Jennison Associates LLC Purchases Shares of 77,401 Amneal Pharmaceuticals, Inc. $AMRX

Jennison Associates LLC acquired a new position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 77,401 shares of the company’s stock, valued at approximately $975,000.

A number of other large investors have also recently made changes to their positions in AMRX. Allspring Global Investments Holdings LLC lifted its position in Amneal Pharmaceuticals by 1,440.0% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,135,799 shares of the company’s stock valued at $11,790,000 after acquiring an additional 1,062,045 shares in the last quarter. Oliver Luxxe Assets LLC acquired a new position in Amneal Pharmaceuticals during the 4th quarter valued at about $1,972,000. AustralianSuper Pty Ltd bought a new stake in Amneal Pharmaceuticals during the 3rd quarter worth approximately $3,238,000. SG Americas Securities LLC raised its stake in shares of Amneal Pharmaceuticals by 2,866.0% in the fourth quarter. SG Americas Securities LLC now owns 784,803 shares of the company’s stock worth $9,889,000 after purchasing an additional 758,343 shares during the last quarter. Finally, Citigroup Inc. raised its stake in shares of Amneal Pharmaceuticals by 55.7% in the third quarter. Citigroup Inc. now owns 282,862 shares of the company’s stock worth $2,831,000 after purchasing an additional 101,166 shares during the last quarter. 31.82% of the stock is owned by institutional investors.

Analyst Ratings Changes

AMRX has been the topic of several analyst reports. Zacks Research cut Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 6th. UBS Group began coverage on Amneal Pharmaceuticals in a research report on Friday, April 17th. They issued a “buy” rating and a $19.00 price target for the company. Truist Financial raised their price objective on Amneal Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Amneal Pharmaceuticals in a report on Wednesday, January 21st. Six research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $15.00.

Amneal Pharmaceuticals Price Performance

Amneal Pharmaceuticals stock opened at $12.83 on Monday. Amneal Pharmaceuticals, Inc. has a 52 week low of $7.02 and a 52 week high of $15.42. The company’s 50 day moving average price is $12.87 and its two-hundred day moving average price is $12.66. The stock has a market cap of $4.04 billion, a P/E ratio of 33.76 and a beta of 1.32.

Amneal Pharmaceuticals (NASDAQ:AMRX) last released its earnings results on Wednesday, April 22nd. The company reported $0.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.15 by $0.11. The company had revenue of $723.00 million during the quarter, compared to analyst estimates of $709.79 million. Amneal Pharmaceuticals had a negative return on equity of 276.67% and a net margin of 4.53%.Amneal Pharmaceuticals has set its FY 2026 guidance at 0.950-1.050 EPS and its Q1 2026 guidance at 0.270-0.270 EPS. On average, equities analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.92 EPS for the current year.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.